CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES
نویسندگان
چکیده
منابع مشابه
Cholinesterase Inhibitors: Drugs Looking for a Disease?
0456 R andomized controlled trials (RCTs) are generally considered to be a robust form of evidence, free from bias, and the trial results are often used as a powerful tool to promote new drugs [1,2]. However, because the inclusion criteria for many RCTs are often very restrictive (for example, trials generally exclude patients with serious concomitant illnesses) and because patients in trials t...
متن کاملReview: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease.
Data extraction Two reviewers extracted data independently about study methods, sources of bias, and outcomes. Sixteen trials included neuropsychiatric outcomes and 18 included functional measures. Neuropsychiatric outcomes were measured with the Neuropsychiatric Inventory (NPI) and the Alzheimer Disease Assessment Scale, noncognitive (ADAS-noncog). Data were combined using weighted mean differ...
متن کاملCholinesterase inhibitors and memory.
A consensus exists that cholinesterase inhibitors (ChEIs) are efficacious for mild to moderate Alzheimer's Disease (AD). Unfortunately, the number of non-responders is large and the therapeutic effect is usually short-lasting. In experimental animals, ChEIs exert three main actions: inhibit cholinesterase (ChE), increase extracellular levels of brain acetylcholine (ACh), improve cognitive proce...
متن کاملCholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease.
OBJECTIVE Examine the effect of cholinesterase inhibitors (ChEIs) on behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD), and compared the dosages of antipsychotics and SSRIs or SNRIs used to treat BPSD in patients with and without ChEIs. MATERIAL AND METHOD The cross-sectional study of Alzheimer patients who had been taking ChEls for at least si...
متن کاملUpdate on Cholinesterase Inhibitors and Treatment of Alzheimer’s Disease
The long-term studies of the cholinesterase inhibitors, Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine), support their ability to delay Alzheimer’s disease (AD) progression during the dementia stage by 1, 1.5, and 2.5 years respectively, which underscores the importance of early detection to optimize quality of life. Cholinesterase inhibitors reduce caregiving burden by de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
سال: 2007
ISSN: 1079-5006,1758-535X
DOI: 10.1093/gerona/62.5.570